DK2909233T3

DK2909233T3 - Polypeptides that can internalize cellularly

Polypeptides that can internalize cellularly Download PDF

Info

Publication number: DK2909233T3
Authority: DK; Denmark
Prior art keywords: alphabody; polypeptides; polypeptide; intracellular; cell
Prior art date: 2012-10-22

Application number

DK13788700.6T

Other languages

Danish (da)

English (en)

Inventor

Stefan Loverix

Philippe Alard

Sabrina Deroo

Klaartje Somers

Ignace Lasters

Johan Desmet

Original Assignee

Complix Nv

Priority date

2012-10-22

Filing date

2013-10-22

Publication date

2017-02-20

2013-10-22 Application filed by Complix Nv filed Critical Complix Nv

2017-02-20 Application granted granted Critical

2017-02-20 Publication of DK2909233T3 publication Critical patent/DK2909233T3/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 474
102000004196 processed proteins & peptides Human genes 0.000 title claims description 472
229920001184 polypeptide Polymers 0.000 title claims description 467
230000003834 intracellular effect Effects 0.000 claims description 266
230000027455 binding Effects 0.000 claims description 180
102000004169 proteins and genes Human genes 0.000 claims description 132
108090000623 proteins and genes Proteins 0.000 claims description 132
125000000539 amino acid group Chemical group 0.000 claims description 127
238000000034 method Methods 0.000 claims description 121
229940024606 amino acid Drugs 0.000 claims description 89
150000001413 amino acids Chemical class 0.000 claims description 85
239000012634 fragment Substances 0.000 claims description 56
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
239000004475 Arginine Substances 0.000 claims description 32
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 32
201000010099 disease Diseases 0.000 claims description 28
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 27
239000008194 pharmaceutical composition Substances 0.000 claims description 24
238000000338 in vitro Methods 0.000 claims description 23
208000035475 disorder Diseases 0.000 claims description 20
230000009870 specific binding Effects 0.000 claims description 17
101100177642 Rattus norvegicus Hgs gene Proteins 0.000 claims description 14
101100129853 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SRB2 gene Proteins 0.000 claims description 14
101100339677 Arabidopsis thaliana HRS1 gene Proteins 0.000 claims description 10
101100129874 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGD1 gene Proteins 0.000 claims description 10
101100129591 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcp6 gene Proteins 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
230000008827 biological function Effects 0.000 claims description 6
125000001931 aliphatic group Chemical group 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
210000004027 cell Anatomy 0.000 description 387
235000001014 amino acid Nutrition 0.000 description 93
235000018102 proteins Nutrition 0.000 description 83
230000000694 effects Effects 0.000 description 57
235000009697 arginine Nutrition 0.000 description 55
206010028980 Neoplasm Diseases 0.000 description 54
101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 53
102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 51
125000005647 linker group Chemical group 0.000 description 47
201000011510 cancer Diseases 0.000 description 42
239000000203 mixture Substances 0.000 description 34
235000018977 lysine Nutrition 0.000 description 33
238000011534 incubation Methods 0.000 description 27
125000003275 alpha amino acid group Chemical group 0.000 description 26
230000030833 cell death Effects 0.000 description 25
208000005017 glioblastoma Diseases 0.000 description 25
150000002669 lysines Chemical class 0.000 description 24
210000004379 membrane Anatomy 0.000 description 24
239000012528 membrane Substances 0.000 description 24
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 23
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 23
229960000310 isoleucine Drugs 0.000 description 23
230000003833 cell viability Effects 0.000 description 22
230000001086 cytosolic effect Effects 0.000 description 22
238000011282 treatment Methods 0.000 description 22
230000006870 function Effects 0.000 description 21
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 20
230000001413 cellular effect Effects 0.000 description 20
239000012909 foetal bovine serum Substances 0.000 description 20
229960002897 heparin Drugs 0.000 description 20
230000002401 inhibitory effect Effects 0.000 description 20
150000007523 nucleic acids Chemical class 0.000 description 20
239000000872 buffer Substances 0.000 description 19
231100000673 dose–response relationship Toxicity 0.000 description 19
229920000669 heparin Polymers 0.000 description 19
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 17
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 17
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 17
238000004519 manufacturing process Methods 0.000 description 17
230000035515 penetration Effects 0.000 description 17
230000008569 process Effects 0.000 description 17
210000002966 serum Anatomy 0.000 description 17
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 16
102000051485 Bcl-2 family Human genes 0.000 description 16
108700038897 Bcl-2 family Proteins 0.000 description 16
230000000903 blocking effect Effects 0.000 description 16
238000002474 experimental method Methods 0.000 description 16
230000003405 preventing effect Effects 0.000 description 16
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 15
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
210000000170 cell membrane Anatomy 0.000 description 15
125000006850 spacer group Chemical group 0.000 description 15
238000005406 washing Methods 0.000 description 15
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 14
238000010790 dilution Methods 0.000 description 14
239000012895 dilution Substances 0.000 description 14
230000000149 penetrating effect Effects 0.000 description 14
230000001225 therapeutic effect Effects 0.000 description 14
239000013598 vector Substances 0.000 description 14
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 13
241000283707 Capra Species 0.000 description 13
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 13
230000003993 interaction Effects 0.000 description 13
230000008823 permeabilization Effects 0.000 description 13
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 12
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 12
230000002424 anti-apoptotic effect Effects 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
230000001404 mediated effect Effects 0.000 description 12
238000012216 screening Methods 0.000 description 12
239000004471 Glycine Substances 0.000 description 11
210000004899 c-terminal region Anatomy 0.000 description 11
230000000875 corresponding effect Effects 0.000 description 11
239000002773 nucleotide Substances 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 11
230000004071 biological effect Effects 0.000 description 10
230000007321 biological mechanism Effects 0.000 description 10
229920002521 macromolecule Polymers 0.000 description 10
210000004940 nucleus Anatomy 0.000 description 10
230000002265 prevention Effects 0.000 description 10
230000011664 signaling Effects 0.000 description 10
239000000126 substance Substances 0.000 description 10
102000005720 Glutathione transferase Human genes 0.000 description 9
108010070675 Glutathione transferase Proteins 0.000 description 9
239000004472 Lysine Substances 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 9
230000006907 apoptotic process Effects 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
230000001976 improved effect Effects 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000000069 prophylactic effect Effects 0.000 description 9
239000002904 solvent Substances 0.000 description 9
208000000389 T-cell leukemia Diseases 0.000 description 8
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
238000000746 purification Methods 0.000 description 8
238000010186 staining Methods 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
108091081062 Repeated sequence (DNA) Proteins 0.000 description 7
238000013461 design Methods 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
-1 lipidoids Substances 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
230000037361 pathway Effects 0.000 description 7
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
230000035899 viability Effects 0.000 description 7
201000009030 Carcinoma Diseases 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
229920002971 Heparan sulfate Polymers 0.000 description 6
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 6
108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 6
102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 6
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
238000000423 cell based assay Methods 0.000 description 6
230000004700 cellular uptake Effects 0.000 description 6
230000002708 enhancing effect Effects 0.000 description 6
238000000099 in vitro assay Methods 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
235000004400 serine Nutrition 0.000 description 6
241000894007 species Species 0.000 description 6
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
230000003213 activating effect Effects 0.000 description 5
238000010171 animal model Methods 0.000 description 5
238000004132 cross linking Methods 0.000 description 5
238000005034 decoration Methods 0.000 description 5
238000005462 in vivo assay Methods 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
239000003446 ligand Substances 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
206010024627 liposarcoma Diseases 0.000 description 5
230000035772 mutation Effects 0.000 description 5
239000008188 pellet Substances 0.000 description 5
230000000861 pro-apoptotic effect Effects 0.000 description 5
235000013930 proline Nutrition 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 4
229920001287 Chondroitin sulfate Polymers 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
206010061902 Pancreatic neoplasm Diseases 0.000 description 4
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
102000007562 Serum Albumin Human genes 0.000 description 4
108010071390 Serum Albumin Proteins 0.000 description 4
229920004890 Triton X-100 Polymers 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000011575 calcium Substances 0.000 description 4
230000006037 cell lysis Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
230000002950 deficient Effects 0.000 description 4
208000037765 diseases and disorders Diseases 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
102000010660 flotillin Human genes 0.000 description 4
108060000864 flotillin Proteins 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
230000004927 fusion Effects 0.000 description 4
208000027866 inflammatory disease Diseases 0.000 description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
201000002528 pancreatic cancer Diseases 0.000 description 4
208000008443 pancreatic carcinoma Diseases 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
230000008288 physiological mechanism Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
102000020313 Cell-Penetrating Peptides Human genes 0.000 description 3
108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
101150048357 Lamp1 gene Proteins 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
239000012124 Opti-MEM Substances 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000006180 TBST buffer Substances 0.000 description 3
102000004338 Transferrin Human genes 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
230000009056 active transport Effects 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
238000003782 apoptosis assay Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000008236 biological pathway Effects 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
239000008004 cell lysis buffer Substances 0.000 description 3
230000033077 cellular process Effects 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000010382 chemical cross-linking Methods 0.000 description 3
229940059329 chondroitin sulfate Drugs 0.000 description 3
238000004624 confocal microscopy Methods 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
238000011033 desalting Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
208000018706 hematopoietic system disease Diseases 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
238000012758 nuclear staining Methods 0.000 description 3
238000012856 packing Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000005522 programmed cell death Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
108020001580 protein domains Proteins 0.000 description 3
230000004850 protein–protein interaction Effects 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000010187 selection method Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
239000012581 transferrin Substances 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 2
208000003200 Adenoma Diseases 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
102000007371 Ataxin-3 Human genes 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000271566 Aves Species 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
230000033616 DNA repair Effects 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000924350 Homo sapiens Alpha-N-acetylglucosaminidase Proteins 0.000 description 2
101000962088 Homo sapiens NBAS subunit of NRZ tethering complex Proteins 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
208000002569 Machado-Joseph Disease Diseases 0.000 description 2
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
208000007054 Medullary Carcinoma Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
208000002151 Pleural effusion Diseases 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
206010043276 Teratoma Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
238000003314 affinity selection Methods 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
230000004900 autophagic degradation Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
208000003362 bronchogenic carcinoma Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
208000002458 carcinoid tumor Diseases 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
230000023402 cell communication Effects 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
230000009087 cell motility Effects 0.000 description 2
230000019522 cellular metabolic process Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000000942 confocal micrograph Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
230000021953 cytokinesis Effects 0.000 description 2
230000021040 cytoplasmic transport Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 2
FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 2
LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000001163 endosome Anatomy 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000006624 extrinsic pathway Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
235000004554 glutamine Nutrition 0.000 description 2
230000034659 glycolysis Effects 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
125000001165 hydrophobic group Chemical group 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000000126 in silico method Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000016507 interphase Effects 0.000 description 2
210000004020 intracellular membrane Anatomy 0.000 description 2
210000003093 intracellular space Anatomy 0.000 description 2
201000003159 intraductal papilloma Diseases 0.000 description 2
230000006623 intrinsic pathway Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000021121 meiosis Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
201000010198 papillary carcinoma Diseases 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000009057 passive transport Effects 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
230000033458 reproduction Effects 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
230000009758 senescence Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000012772 sequence design Methods 0.000 description 2
238000003892 spreading Methods 0.000 description 2
230000007480 spreading Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000008685 targeting Effects 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
YYDMSFVTLYEPOH-UHFFFAOYSA-N 2,5-dioxo-1-propanoyloxypyrrolidine-3-sulfonic acid Chemical compound CCC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O YYDMSFVTLYEPOH-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
ZVEUWSJUXREOBK-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound NCC(O)=O.OC[C@H](N)C(O)=O ZVEUWSJUXREOBK-DKWTVANSSA-N 0.000 description 1
RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 1
208000023769 AA amyloidosis Diseases 0.000 description 1
HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
208000018282 ACys amyloidosis Diseases 0.000 description 1
101800000263 Acidic protein Proteins 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002025 Amyloidosis senile Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
102000007370 Ataxin2 Human genes 0.000 description 1
102000014461 Ataxins Human genes 0.000 description 1
108010078286 Ataxins Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
102000004321 Atrophin-1 Human genes 0.000 description 1
108090000806 Atrophin-1 Proteins 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
102100023932 Bcl-2-like protein 2 Human genes 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
208000007690 Brenner tumor Diseases 0.000 description 1
206010073258 Brenner tumour Diseases 0.000 description 1
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
206010007509 Cardiac amyloidosis Diseases 0.000 description 1
102000004039 Caspase-9 Human genes 0.000 description 1
108090000566 Caspase-9 Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008025 Cerebellar ataxia Diseases 0.000 description 1
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
102000009058 Death Domain Receptors Human genes 0.000 description 1
108010049207 Death Domain Receptors Proteins 0.000 description 1
201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
208000019872 Drug Eruptions Diseases 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
206010016202 Familial Amyloidosis Diseases 0.000 description 1
208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
108010039471 Fas Ligand Protein Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000007659 Fibroadenoma Diseases 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 description 1
208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000032838 Hereditary amyloidosis with primary renal involvement Diseases 0.000 description 1
208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101000904691 Homo sapiens Bcl-2-like protein 2 Proteins 0.000 description 1
101000740224 Homo sapiens Protein SCAI Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000000675 Krukenberg Tumor Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
206010027462 Metastases to ovary Diseases 0.000 description 1
201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000005927 Myosarcoma Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241000009328 Perro Species 0.000 description 1
208000002163 Phyllodes Tumor Diseases 0.000 description 1
206010071776 Phyllodes tumour Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
206010035610 Pleural Neoplasms Diseases 0.000 description 1
208000002664 Pleural Solitary Fibrous Tumor Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102100035548 Protein Bop Human genes 0.000 description 1
108050008794 Protein Bop Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102100037197 Protein SCAI Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
201000003629 Spinocerebellar ataxia type 8 Diseases 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010049418 Sudden Cardiac Death Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
201000000331 Testicular germ cell cancer Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
206010070517 Type 2 lepra reaction Diseases 0.000 description 1
108010065282 UDP xylose-protein xylosyltransferase Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010048215 Xanthomatosis Diseases 0.000 description 1
102000010199 Xylosyltransferases Human genes 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
208000012018 Yolk sac tumor Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000008850 allosteric inhibition Effects 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000004670 arteriolosclerosis Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
201000004982 autoimmune uveitis Diseases 0.000 description 1
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
108700000711 bcl-X Proteins 0.000 description 1
102000055104 bcl-X Human genes 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
201000007180 bile duct carcinoma Diseases 0.000 description 1
230000009141 biological interaction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
201000005389 breast carcinoma in situ Diseases 0.000 description 1
201000003149 breast fibroadenoma Diseases 0.000 description 1
208000020670 canker sore Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000002041 carbon nanotube Substances 0.000 description 1
229910021393 carbon nanotube Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000004656 cell transport Effects 0.000 description 1
238000003570 cell viability assay Methods 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
229940107200 chondroitin sulfates Drugs 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000004732 colorectal carcinogenesis Effects 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
208000007321 cystadenofibroma Diseases 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000007418 data mining Methods 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
201000007273 ductal carcinoma in situ Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
208000001991 endodermal sinus tumor Diseases 0.000 description 1
208000027858 endometrioid tumor Diseases 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
201000007891 familial visceral amyloidosis Diseases 0.000 description 1
201000010972 female reproductive endometrioid cancer Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005908 glyceryl ester group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
208000003064 gonadoblastoma Diseases 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
201000002222 hemangioblastoma Diseases 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
238000005734 heterodimerization reaction Methods 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
208000015210 hypertensive heart disease Diseases 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000013152 interventional procedure Methods 0.000 description 1
210000005061 intracellular organelle Anatomy 0.000 description 1
230000006525 intracellular process Effects 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000000111 isothermal titration calorimetry Methods 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000011059 lobular neoplasia Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
208000006178 malignant mesothelioma Diseases 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000001457 metallic cations Chemical class 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
201000002335 monodermal teratoma Diseases 0.000 description 1
208000022669 mucinous neoplasm Diseases 0.000 description 1
201000002077 muscle cancer Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
230000002956 necrotizing effect Effects 0.000 description 1
208000012108 neoplastic polyp Diseases 0.000 description 1
201000011519 neuroendocrine tumor Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100001143 noxa Toxicity 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
208000025207 ovarian monodermal teratoma Diseases 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
208000021255 pancreatic insulinoma Diseases 0.000 description 1
208000004019 papillary adenocarcinoma Diseases 0.000 description 1
208000012111 paraneoplastic syndrome Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
101150040383 pel2 gene Proteins 0.000 description 1
101150050446 pelB gene Proteins 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
210000004224 pleura Anatomy 0.000 description 1
201000003437 pleural cancer Diseases 0.000 description 1
201000003144 pneumothorax Diseases 0.000 description 1
230000007824 polyneuropathy Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
201000008662 sclerosing adenosis of breast Diseases 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000007727 signaling mechanism Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
208000014653 solitary fibrous tumor Diseases 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
201000003632 spinocerebellar ataxia type 7 Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
208000001644 thecoma Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
201000007905 transthyretin amyloidosis Diseases 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
201000007423 tubular adenocarcinoma Diseases 0.000 description 1
230000010304 tumor cell viability Effects 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
231100000747 viability assay Toxicity 0.000 description 1
238000003026 viability measurement method Methods 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1